Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Chemoradiotherapy for Advanced Esophageal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02297217
Recruitment Status : Recruiting
First Posted : November 21, 2014
Last Update Posted : November 4, 2020
Sponsor:
Information provided by (Responsible Party):
Marc Kerba, AHS Cancer Control Alberta

Brief Summary:
This study aims to show that the addition of carboplatin and paclitaxel chemotherapy to a palliative course of external beam radiation treatment improves both dysphagia relief and patient quality of life in patients with unresectable esophageal cancer.

Condition or disease Intervention/treatment Phase
Esophageal Cancer Drug: Carboplatin and Taxol (paclitaxel) Radiation: External Beam Radiation Phase 2

Detailed Description:
Patients with carcinoma of the esophagus not suitable for definitive radical treatment who have symptomatic dysphagia requiring locoregional palliation, and who have no contra-indications to chemo-radiotherapy will be offered Carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously on days 1 and 8 concurrent with external beam radiation therapy of 30Gy/10 fractions over two weeks where the primary goal is relief of dysphagia and other outcomes include toxicity, quality of life and metabolomics.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study of Palliative Chemo-Radiotherapy With Carbo-Taxol in Non-Curative Cancer of the Esophagus
Actual Study Start Date : November 21, 2019
Estimated Primary Completion Date : April 30, 2022
Estimated Study Completion Date : April 30, 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Chemotherapy with Concurrent Radiation
Carboplatin and paclitaxel will be administered intravenously on Days 1 and 8 while radiation therapy is administered
Drug: Carboplatin and Taxol (paclitaxel)
Patients will receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously on Days 1 and 8. Patients are seen for 2 weekly Treatment Visits during concurrent chemo-radiation then every 28 days until the End of Study Visit, approximately 6 months after Treatment Visit 1. Preparation and administration of chemotherapy will be according to local site standard of care.

Radiation: External Beam Radiation
Patients will receive external beam radiation therapy of 30Gy/10 fractions over two weeks (or reduced to 25 Gy/10 fractions if acute toxicity parameters are met during the run-in) and receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously on Days 1 and 8. Treatment will be planned, prescribed and delivered using standard 3D radiotherapy planning techniques to encompass the primary tumor and surrounding clinical target volume. Patients are seen for 2 weekly Treatment Visits during concurrent chemo-radiation then every 28 days until the End of Study Visit, approximately 6 months after Treatment Visit 1.




Primary Outcome Measures :
  1. Proportion of patients who achieve relief of dysphagia [ Time Frame: up to day 85 ]
    Will be measured as the proportion of patients who achieve relief of dysphagia, defined as improvement of at least one point on the Mellow Dysphagia Score, measured at Day 57 after the start of radiotherapy, and maintained for at least 28 calendar days (until the Day 85 visit).


Secondary Outcome Measures :
  1. Dysphagia progression free survival [ Time Frame: 6 Months ]

    Will be measured from screening to the time of first progression of dysphagia. Progression of dysphagia will be defined as follows:

    • A drop of at least 1 point on the 5 point Mellow Dysphagia Score,
    • Stricture requiring intervention, or
    • Death,

    Other secondary objectives as follows:

    Time to achieving any response in dysphagia after treatment as measured by an improvement of at least 1 point on the 5 point Mellow Dysphagia Score. Number of patients receiving secondary treatment (radiation, chemotherapy or stenting), Utility assessments pre to post treatment and at 3 and 6 months, Quality of life differences post treatment and at 3 and 6 months. Measures of biological/serological correlates of response, Acute and late toxicity.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Biopsy proven carcinoma of the esophagus.
  2. Not a candidate for radical/curative treatment due to the advanced nature of the disease, presence of metastases, or intercurrent illness.
  3. Symptomatic patients with Mellow Dysphagia Scores of ≥ 1 i.e. able to eat only some solids.
  4. ECOG Performance status ≤ 2.
  5. Patients able to begin treatment within 14 days of signing the informed consent form.
  6. Patient is at least 18 years old.
  7. Hematological function as defined by the following laboratory parameters:

    • Hemoglobin > 100g/L
    • Platelet count > 100x10E9/L
    • Absolute neutrophil count > 1.5x10E9/L
  8. Renal function to undergo chemotherapy as defined by the following laboratory parameters:

    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5x the upper limit of institutional normal (≤ 5 if liver metastases)
    • Total bilirubin ≤ 1.5x the upper limit of institutional normal
    • Calculated creatinine clearance ≥ 50 mL/min using the Cockcroft-Gault formula
  9. Patients capable of childbearing are using adequate contraception.
  10. Written and informed consent of patient.

Exclusion Criteria:

  1. Previous radiotherapy delivered to the chest.
  2. Synchronous active malignancies.
  3. Pregnant or lactating patients: women of child bearing potential must have a negative serum pregnancy test within 7 days of Treatment Visit 1. Women or men of child bearing potential must use effective contraception (defined by the use of two birth control methods, which can be either two barrier methods or a barrier method plus a hormonal method to prevent pregnancy). Subjects must start using birth control from the time they have signed the Informed Consent Form prior to start of therapy until 120 days post completion of study therapy or study discontinuation, which must be documented in the eCRF.
  4. Patients unfit for any treatment component, including absolute contraindications for radiotherapy or Connective Tissue Disease.
  5. Tracheo-esophageal fistula.
  6. Esophageal stents in situ.
  7. Previous chemotherapy for esophageal cancer
  8. Unable to complete surveys in English without aid of interpreter.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02297217


Contacts
Layout table for location contacts
Contact: Marc Kerba, MD 403 521 3164 marc.kerba@albertahealthservices.ca
Contact: Jennifer Spratlin, MD 780-432-8514 jennifer.spratlin@albertahealthservices.ca

Locations
Layout table for location information
Canada, Alberta
Tom Baker Cancer Centre Recruiting
Calgary, Alberta, Canada, T2N 4N2
Contact: Marc Kerba, MD    403-521-3164    marc.kerba@ahs.ca   
Contact: Heather Cooper    403-521-3889    heather.cooper@ahs.ca   
Sponsors and Collaborators
AHS Cancer Control Alberta
Investigators
Layout table for investigator information
Principal Investigator: Marc Kerba, MD 403 521 3164
Layout table for additonal information
Responsible Party: Marc Kerba, MD, AHS Cancer Control Alberta
ClinicalTrials.gov Identifier: NCT02297217    
Other Study ID Numbers: HREBA.CC-14-0122
First Posted: November 21, 2014    Key Record Dates
Last Update Posted: November 4, 2020
Last Verified: November 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Esophageal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Head and Neck Neoplasms
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases
Paclitaxel
Carboplatin
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action